Topic : Business expansion
– Advancing First-Order Treg CD8 Modulators to Restore Immune Balance
SEATTLE, Oct. 27, 2021 / PRNewswire / –Mozart Therapeutics, Inc., a new biopharmaceutical company targeting a novel immune pathway to change the course of autoimmune and inflammatory disease, today announced $ 55million seriesA funding led by ARCH Venture Partners, a Series A investor, and Sofinnova Partners. Other investors include EliLilly & Company, MRL Ventures Fund (the fund of Merck & Co., Inc., focused on early stage therapies), Leaps by Bayer, Altitude Life Science Ventures, Alexandria Venture Investments.
Mozart was founded on the work of Mark M. Davis, Ph.D., a leading global expert in the field of T cell biology. Professor Davis has discovered that a network of CD8 T regulatory cells plays a key role in the surveillance, recognition and elimination of autoractive and poorly active pathogenic immune cells, which are a root cause of autoimmune and inflammatory diseases.1. The technology was licensed to Mozart so the company could develop therapeutic candidates that target and modulate this network for the treatment of autoimmune and inflammatory diseases.
The company will use Series A funds to advance its primary Treg CD8 modulator to the clinic while advancing other programs generated from its new platform.
Mozart is doing something truly unique to change the paradigm for treating patients with autoimmune and inflammatory diseases. We aim to redefine and restore the balance of the immune system by taking advantage of a new avenue to develop first-class CD8 Treg modulators as disease-modifying therapies. Our goal is to address an unmet need for a whole host of diseases, ”said KatieFanning, CEO of MozartTherapeutics and a seasoned professional in the biotechnology industry for 35 years. I am grateful to have the financial support of a strong group of leading healthcare investors. They bring exceptional industrial and strategic focus to advance our therapeutic candidates through development and bring them into the clinic.
Modulation of the CD8 Treg network represents a new way to tackle a root cause of immune system dysregulation. We are pleased to support the advancement of Mozart’s groundbreaking research, which could have a significant impact on the evolution of a wide range of diseases, said SteveGillis, Ph.D., Managing Director of ARCH Venture Partners and Chairman of the Mozart Board of Directors.
Given the large and tense need for effective therapies for autoimmune and inflammatory diseases, it is exciting to see Mozart’s new and distinct approach to meeting this challenge, said HenrijetteRichter, associate director at Sofinnova Partners. We are delighted to join this consortium of world-class investors and look forward to supporting the team to establish Mozart as a world-class leader in the field of CD8 T regulatory cell network modulation.
Mozart also announced the formation of a Scientific Advisory Board, composed of key opinion leaders in the fields of immunology, T cell biology, immune modulation and protein engineering, and its council. Board of Directors, made up of prominent biotechnology investors and pharmaceutical industry veterans.
Mozart Scientific Advisory Board:
- Mark M. Davis, Ph.D., Scientific Co-Founder, Director of the Stanford Institute for Immunology, Transplantation and Infection (ITI), Avery Family Professor of Immunology and Research Fellow at Howard Hughes Medical Institute.
- K. ChristopherGarcia, Ph.D., Scientific Co-Founder, Professor of Molecular and Cellular Physiology and Structural Biology, Faculty of Medicine, University of Stanford, and a researcher at the Howard Hughes Medical Institute.
- CalvinKuo, Ph.D., Scientific Co-Founder, Maureen Lyles D’Ambrogio Professor of Medicine (Hmatology), Faculty of Medicine, University of Stanford.
- MichaelRosenblum, Ph.D., professor of dermatology and vice president of research at the University of California San Francisco (UCSF)
Mozart Board of Directors:
- StevenGillis, Ph.D., prsident, ARCH Venture Partners
- TomDaniel, MD
- PeterDudek, Ph.D., MRL Ventures Fund
- JulieGilmore, Ph.D., Eli Lilly & Company
- LucioIannone, Ph.D., Leaps by Bayer
- HenrijetteRichter, Sofinnova Partners
About TregCD8 modulators
CD8 Treg modulators are disease modifying therapeutic molecules that selectively target the CD8 regulatory T cell network to counteract the early events of the autoimmune inflammatory cascade. Dysregulation of this network plays a key role in the pathology of autoimmune and inflammatory diseases. CD8 Treg modulators are designed to restore the intrinsic functions of CD8T regulatory cells to suppress and eliminate pathogenic immune cells, providing long-lasting control of autoimmune and inflammatory diseases.
MozartTherapeutics is focused on the development of autoimmune and inflammatory disease-modifying therapies that work by targeting a novel regulatory immune pathway. The therapeutic target of Mozart’s main program concerns autoimmune mediated gastrointestinal disorders. The company’s registered office is Seattle, in the state of Washington, in the United States. For more information, visit www.mozart-tx.com and follow the company on LinkedIn @ Mozart-tx.
1SaligramaN, DavisMMet al.,Nature2019:https://doi.org/10.1038/s41586-019-1467-x
These press releases may also be of interest to you
Communiqu sent on October 26, 2021 9:29 pm and distributed by: